Patent intelligence · US
US 12109197
Combinations of β-lactam compounds and probenecid and uses thereof
Combinations of β-lactam compounds and probenecid and uses thereof
Patent details — US 12109197
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 8, 2024
- Expiration
- Oct 3, 2044
- Claims
- 10
- CPC classes
- A61K, A61K31/145, A61K31/195, A61K31/407
Quick answer
US 12109197 (Combinations of β-lactam compounds and probenecid and uses thereof) is held by Iterum Therapeutics International Limited. Status: granted. Granted Oct 8, 2024. Expires Oct 3, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K31/145, A61K31/195, A61K31/407, A61K31/424, A61K31/43
More from Iterum Therapeutics International Limited
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12109197?
US 12109197 (Combinations of β-lactam compounds and probenecid and uses thereof) is held by Iterum Therapeutics International Limited. Status: granted. Granted Oct 8, 2024. Expires Oct 3, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12109197?
Iterum Therapeutics International Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 12109197 expire?
Our index shows an expiration date of Oct 3, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.